These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 2103499)
1. Human monoclonal antibodies and engineered antibodies in the management of cancer. James K Semin Cancer Biol; 1990 Jun; 1(3):243-53. PubMed ID: 2103499 [TBL] [Abstract][Full Text] [Related]
2. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
3. Prospects for the therapeutic use of human monoclonal antibodies. Larrick JW; Bourla JM J Biol Response Mod; 1986 Oct; 5(5):379-93. PubMed ID: 3534144 [TBL] [Abstract][Full Text] [Related]
4. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes. de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012 [TBL] [Abstract][Full Text] [Related]
5. Engineered therapeutic antibodies with improved effector functions. Kubota T; Niwa R; Satoh M; Akinaga S; Shitara K; Hanai N Cancer Sci; 2009 Sep; 100(9):1566-72. PubMed ID: 19538497 [TBL] [Abstract][Full Text] [Related]
6. Antibody engineering: facing new challenges in cancer therapy. Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728 [TBL] [Abstract][Full Text] [Related]
7. Molecular engineering and design of therapeutic antibodies. Presta LG Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541 [TBL] [Abstract][Full Text] [Related]
8. Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Kershaw MH; Trapani JA; Smyth MJ Ther Immunol; 1995 Jun; 2(3):173-81. PubMed ID: 8885135 [TBL] [Abstract][Full Text] [Related]
9. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Khawli LA; Hu P; Epstein AL Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951 [TBL] [Abstract][Full Text] [Related]
10. Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies. Vollmers HP; Brändlein S Hum Antibodies; 2002; 11(4):131-42. PubMed ID: 12775893 [TBL] [Abstract][Full Text] [Related]
11. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Schuster M; Umana P; Ferrara C; Brünker P; Gerdes C; Waxenecker G; Wiederkum S; Schwager C; Loibner H; Himmler G; Mudde GC Cancer Res; 2005 Sep; 65(17):7934-41. PubMed ID: 16140965 [TBL] [Abstract][Full Text] [Related]
12. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Lonberg N; Taylor LD; Harding FA; Trounstine M; Higgins KM; Schramm SR; Kuo CC; Mashayekh R; Wymore K; McCabe JG Nature; 1994 Apr; 368(6474):856-9. PubMed ID: 8159246 [TBL] [Abstract][Full Text] [Related]
13. Engineered antibodies take center stage. Huston JS; George AJ Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424 [TBL] [Abstract][Full Text] [Related]